[1] E. J. Fuchs, “Transplantation tolerance: From theory to clinic,” Immunol. Rev., vol. 258, no. 1, pp. 64–79, 2014, doi: 10.1111/imr.12154.
[2] J. F. Gummert, T. Ikonen, and R. E. Morris, “Newer immunosuppressive drugs: A review,” J. Am. Soc. Nephrol., vol. 10, no. 6, pp. 1366–1380, 1999.
[3] John C. Wu, “Mycophenolate mofetil: Molecular mechanisms of action,” Perspect. Drug Discov. Des., vol. 2, pp. 185–204, 1994, doi: 10.1191/0961203305lu2109oa.
[4] A. C. B. Cato and E. Wade, “Molecular mechanisms of anti-inflammatory action of glucocorticoids,” BioEssays, vol. 18, no. 5, pp. 371–378, 1996, doi: 10.1002/bies.950180507.
[5] C. Vitale et al., “The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity,” Eur. J. Immunol., vol. 34, no. 11, pp. 3028–3038, 2004, doi: 10.1002/eji.200425418.
[6] L. Chiossone et al., “Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: Evidence for different susceptibility of IL-2- versus IL-15-activated NK cells,” Blood, vol. 109, no. 9, pp. 3767–3775, 2007, doi: 10.1182/blood-2006-07-037846.
[7] K. Le Blanc and D. Mougiakakos, “Multipotent mesenchymal stromal cells and the innate immune system,” Nat. Rev. Immunol., vol. 12, no. 5, pp. 383–396, 2012, doi: 10.1038/nri3209.
[8] Y. Shi et al., “Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair,” Cell Res., vol. 20, no. 5, pp. 510–518, 2010, doi: 10.1038/cr.2010.44.
[9] A. Klimczak and U. Kozlowska, “Mesenchymal stromal cells and tissue-specific progenitor cells: Their role in tissue homeostasis,” Stem Cells Int., vol. 2016, 2016, doi: 10.1155/2016/4285215.
[10] M. Najar, G. Raicevic, H. Fayyad-Kazan, D. Bron, M. Toungouz, and L. Lagneaux, “Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells,” Cytotherapy, vol. 18, no. 2, pp. 160–171, 2016, doi: 10.1016/j.jcyt.2015.10.011.
[11] J. Bienvenu, G. Monneret, N. Fabien, and J. P. Revillard, “The Clinical Usefulness of the Measurement of Cytokines,” Clin. Chem. Lab. Med., vol. 38, no. 4, pp. 267–285, 2000, doi: 10.1515/CCLM.2000.040.
[12] M. W. Lee, S. Ryu, D. S. Kim, K. W. Sung, H. H. Koo, and K. H. Yoo, “Strategies to improve the immunosuppressive properties of human mesenchymal stem cells,” Stem Cell Res. Ther., vol. 6, no. 1, p. 179, 2015, doi: 10.1186/s13287-015-0178-y.
[13] A. Bernards et al., “A Class I Antigen, HLA-G, Expressed in Human Trophoblasts,” Science (80-. )., vol. 3860, pp. 0–3, 1989.
[14] C. L. Aldrich, “HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage,” Mol. Hum. Reprod., vol. 7, no. 12, pp. 1167–1172, 2001, doi: 10.1093/molehr/7.12.1167.
[15] A. Ishitani and D. E. Geraghty, “Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens,” Proc. Natl. Acad. Sci. U. S. A., vol. 89, no. 9, pp. 3947–3951, 1992, doi: 10.1073/pnas.89.9.3947.
[16] G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, “MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2,” Blood, vol. 113, no. 26, pp. 6576–6583, 2009, doi: 10.1182/blood-2009-02-203943.
[17] Kuschner, “乳鼠心肌提取 HHS Public Access,” Physiol. Behav., vol. 176, no. 3, pp. 139–148, 2017, doi: 10.1016/j.physbeh.2017.03.040.
[18] G. Amodio and S. Gregori, “Distinctive Immunological Functions of HLA-G,” 2011.
[19] C. Hu and L. Li, “Preconditioning influences mesenchymal stem cell properties in vitro and in vivo,” J. Cell. Mol. Med., vol. 22, no. 3, pp. 1428–1442, 2018, doi: 10.1111/jcmm.13492.
[20] C. C. Wyles, M. T. Houdek, S. P. Wyles, E. R. Wagner, A. Behfar, and R. J. Sierra, “Differential Cytotoxicity of Corticosteroids on Human Mesenchymal Stem Cells,” Clinical Orthopaedics and Related Research, vol. 473, no. 3. pp. 1155–1164, 2015, doi: 10.1007/s11999-014-3925-y.
[21] N. Shintani and E. B. Hunziker, “Differential effects of dexamethasone on the chondrogenesis of mesenchymal stromal cells: Influence of microenvironment, tissue origin and growth factor,” Eur. Cells Mater., vol. 22, pp. 302–320, 2011, doi: 10.22203/eCM.v022a23.
[22] Y. Xiao, V. Peperzak, L. van Rijn, J. Borst, and J. de Bruijn, “Dexamethasone treatment during the expansion phase sustains stemness of mesenchymal stem cells from human bone marrow,” Cell Res., vol. 18, no. S1, pp. S116–S116, 2008, doi: 10.1038/cr.2008.206.
[23] S. B. Nandy, S. Mohanty, M. Singh, M. Behari, and B. Airan, “Fibroblast Growth Factor-2 alone as an efficient inducer for differentiation of human bone marrow mesenchymal stem cells into dopaminergic neurons,” pp. 1–10, 2014.
[24] S. Rawat, P. Srivastava, S. Mohanty, P. Prabha, S. Gupta, and U. Kanga, “A comparative study on immunomodulatory potential of tissue specific hMSCs: Role of HLA-G Mesenchymal Stem Cells in immunomodulation: A potential candidate for therapeutic intervention? View project Evaluation of therapeutic potential of tissue specific M,” IOSR J. Dent. Med. Sci. e-ISSN, vol. 17, no. 6, pp. 32–40, 2018, doi: 10.9790/0853-1706143240.
[25] A. Kakkar, P. Sharma, M. M. Sankar, O. Kharbanda, and S. Mohanty, “Effect of Hypoxia on Stemness and Differentiation of Dental Pulp Derived Stem Cells,” IOSR J. Dent. Med. Sci., vol. 15, no. 08, pp. 102–111, 2016, doi: 10.9790/0853-150807102111.
[26] W. Chen et al., “Immunomodulatory effects of mesenchymal stromal cells-derived exosome,” Immunol. Res., vol. 64, no. 4, pp. 831–840, 2016, doi: 10.1007/s12026-016-8798-6.
[27] M. Dominici et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006, doi: 10.1080/14653240600855905.
[28] K. Le Blanc et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008, doi: 10.1016/S0140-6736(08)60690-X.
[29] Y. Shi, J. Su, A. I. Roberts, P. Shou, A. B. Rabson, and G. Ren, “How mesenchymal stem cells interact with tissue immune responses,” Trends Immunol., vol. 33, no. 3, pp. 136–143, 2012, doi: 10.1016/j.it.2011.11.004.
[30] X. Chen et al., “The interaction between mesenchymal stem cells and steroids during inflammation.,” Cell Death Dis., vol. 5, pp. 1–12, 2014, doi: 10.1038/cddis.2013.537.
[31] T. H. Lin et al., “Decreased osteogenesis in mesenchymal stem cells derived from the aged mouse is associated with enhanced NF-κB activity,” J. Orthop. Res., vol. 35, no. 2, pp. 281–288, 2017, doi: 10.1002/jor.23270.
[32] W. K. Chan, A. Sik-Yin Lau, J. Chun-Bong Li, H. Ka-Wai Law, Y. L. Lau, and G. Chi-Fung Chan, “MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-γ challenge,” Exp. Hematol., vol. 36, no. 11, pp. 1545–1555, 2008, doi: 10.1016/j.exphem.2008.06.008.
[33] S. J. Prasanna, D. Gopalakrishnan, S. R. Shankar, and A. B. Vasandan, “Pro-inflammatory cytokines, IFNγ and TNFα, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially,” PLoS One, vol. 5, no. 2, 2010, doi: 10.1371/journal.pone.0009016.
[34] N. Schneider et al., “Dexamethasone and Azathioprine Promote Cytoskeletal Changes and Affect Mesenchymal Stem Cell Migratory Behavior,” pp. 1–20, 2015, doi: 10.1371/journal.pone.0120538.
[35] A. Akhter, R. M. Faridi, V. Das, A. Pandey, S. Naik, and S. Agrawal, “In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage,” no. 8, pp. 126–135, 2012, doi: 10.1111/j.1399-0039.2012.01884.x.
[36] A. Akhter, V. Das, A. Pandey, and S. Agrawal, “Effect of Glucocorticoids on Transcriptional Status of HLA-G in Human Trophoblast Cells from Full Term Placenta,” vol. 10, no. 4, pp. 223–229, 2010.
[37] H. Wang, B. Pang, Y. Li, D. Zhu, T. Pang, and Y. Liu, “Dexamethasone has variable effects on mesenchymal stromal cells,” Cytotherapy, vol. 14, no. 4, pp. 423–430, 2012, doi: 10.3109/14653249.2011.652735.
[38] C. C. Wyles, M. T. Houdek, S. P. Wyles, E. R. Wagner, A. Behfar, and R. J. Sierra, “Differential Cytotoxicity of Corticosteroids on Human Mesenchymal Stem Cells,” Clin. Orthop. Relat. Res., vol. 473, no. 3, pp. 1155–1164, 2015, doi: 10.1007/s11999-014-3925-y.
[39] I. H. Song and S. Y. Kim, “Effects of Dexamethasone on Proliferation of Mesenchymal Stem Cells in Long Term Culture,” Korean J. Phys. Anthropol., vol. 20, no. 4, p. 311, 2007, doi: 10.11637/kjpa.2007.20.4.311.
[40] G. Papacrhistou, S. Anagnostou, and T. Katsorhis, “The effect of intraarticular hydrocortisone injection on the articular cartilage of rabbits,” Acta Orthop. Scand. Suppl., vol. 68, no. 275, pp. 132–134, 1997, doi: 10.1080/17453674.1997.11744766.
[41] X. Lu et al., “PGE2 Promotes the migration of mesenchymal stem cells through the activation of FAK and ERK1/2 Pathway,” Stem Cells Int., vol. 2017, 2017, doi: 10.1155/2017/8178643.
[42] D. Hong et al., “Osteoblastogenic effects of dexamethasone through upregulation of TAZ expression in rat mesenchymal stem cells,” J. Steroid Biochem. Mol. Biol., vol. 116, no. 1–2, pp. 86–92, 2009, doi: 10.1016/j.jsbmb.2009.05.007.
[43] S. Patel, Z. F. Xi, E. Y. Seo, D. McGaughey, and J. A. Segre, “Klf4 and corticosteroids activate an overlapping set of transcriptional targets to accelerate in utero epidermal barrier acquisition,” Proc. Natl. Acad. Sci. U. S. A., vol. 103, no. 49, pp. 18668–18673, 2006, doi: 10.1073/pnas.0608658103.
[44] S. Ma, N. Xie, W. Li, B. Yuan, Y. Shi, and Y. Wang, “Immunobiology of mesenchymal stem cells,” Cell Death Differ., vol. 21, no. 2, pp. 216–225, 2014, doi: 10.1038/cdd.2013.158.
[45] H. Sheng et al., “A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1,” Cell Res., vol. 18, no. 8, pp. 846–857, 2008, doi: 10.1038/cr.2008.80.
[46] L. Meesuk, C. Tantrawatpan, P. Kheolamai, and S. Manochantr, “The immunosuppressive capacity of human mesenchymal stromal cells derived from amnion and bone marrow,” Biochem. Biophys. Reports, vol. 8, pp. 34–40, 2016, doi: 10.1016/j.bbrep.2016.07.019.
[47] J. A. Ankrum, R. G. Dastidar, J. F. Ong, O. Levy, and J. M. Karp, “Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids,” Sci. Rep., vol. 4, no. April, 2014, doi: 10.1038/srep04645.
[48] P. Moreau et al., “Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts,” Transplant. Proc., vol. 33, no. 3, pp. 2277–2280, 2001, doi: 10.1016/S0041-1345(01)01990-X.
[49] C. M. Michelo et al., “Added effects of dexamethasone and mesenchymal stem cells on early Natural Killer cell activation,” Transpl. Immunol., vol. 37, pp. 1–9, 2016, doi: 10.1016/j.trim.2016.04.008.